6 results about "Human organism" patented technology

Aspects of the application provide dual inhibitor anti-trypsin 1 / trypsin 2 antibodies and methods of using the same for treating pancreatitis. Other aspects of the application provide engineered non-human organisms encoding a human trypsin 1 protein.

Aspects of the application provide dual inhibitor anti-trypsin 1 / trypsin 2 antibodies and methods of using the same for treating pancreatitis. Other aspects of the application provide engineered non-human organisms encoding a human trypsin 1 protein.

The invention relates to a pharmaceutical composition comprising at least one pharmaceutically active ingredient which is completely dissolved in a solvent phase, characterized in that the pharmaceutically active ingredient is in particular selected from the group of fluorinated heteroaryl amides and the solvent phase is formulated as a solvent mixture and comprises at least one first solvent and a second solvent which is different from the first solvent, wherein the first solvent comprises a C1 to C15-alcohol, wherein the second solvent comprises an organic carbonate, and wherein the first solvent is present in a proportion of 50 to 95 % by weight and wherein the second solvent is present in a proportion of 5 to 50 % by weight, in each case based on the sum of the solvents in the solvent phase.

The present invention relates to an optimized nucleic acid molecule encoding a Responder protein under the control of a promoter that is post-meiotically active during spermiogenesis, a host cell or non-human organism comprising the nucleic acid molecule as well as the production of a male or female transgenic non-human organism employing the nucleic acid molecule.

The present invention relates to a pharmaceutical composition comprising at least one pharmaceutically active ingredient that is completely soluble in a solvent phase, characterized in that the pharmaceutically active ingredient is in particular from the group of fluorinated heteroaryl amides, and the solvent phase is constituted as a solvent mixture and comprises at least one first solvent and a second solvent different from the first solvent, wherein the first solvent comprises a C1-C15 alcohol and the second solvent comprises an organic carbonate, and wherein the first solvent is present in a proportion of 50% to 95% by weight and the second solvent is present in a proportion of 5% to 50% by weight, in each case based on the total amount of solvents in the solvent phase.

The invention relates to a method for production of acetyl phosphate from renewable or next generation feedstocks, comprising enzymatically converting a non-phosphorylated carbohydrate into acetyl phosphate and a product, with a phosphoketolase. In embodiments, the phosphoketolase comprises at least one mutation in its active site preferably enabling an increased affinity and / or increased phosphoketolase activity for a non-phosphorylated carbohydrate, such as i) D-fructose, (ii) D-erythrulose or (iii) glycolaldehyde, compared to a wild- type phosphoketolase sequence. The invention further relates to a phosphoketolase enzyme comprising in its active site the mutation(s) H548N, N549D, H256Y, T2A:16T:H260Y:H548N, H548Y, H260Y:H548Y, H256Y:H260Y:H548Y, H142N:E153D and / or T2A:16T:H260Y:H548Y and its use for producing acetyl phosphate from a non-phosphorylated carbohydrate. The invention further relates to non-human organisms, preferably a microorganism, comprising a gene encoding and optionally expressing said phosphoketolase enzyme and compositions comprising the same.